The U.S. Meals and Drug Administration has expanded the emergency use authorization of Regeneron Prescription drugs Inc’s COVID-19 antibody cocktail, enabling its use as a preventive remedy for the sickness in sure individuals.
The corporate stated the authorization permits the remedy for use in individuals uncovered to an contaminated particular person, or who’re at excessive danger of publicity to an contaminated particular person in settings corresponding to nursing houses or prisons.
The combo remedy, REGEN-COV, was licensed in November for emergency use to deal with individuals with mild-to-moderate COVID-19 in america.
REGEN-COV, a mix of casirivimab and imdevimab, protected family contacts from publicity to SARS-CoV-2, with 72% safety in opposition to symptomatic infections within the first week, and 93% after that, based on trial information launched by the corporate in April.
Regeneron stated the expanded authorization will assist deal with the wants of immunocompromised individuals, together with these taking immunosuppressive medicines, whose our bodies might not mount an sufficient response to COVID-19 vaccination.
(Reporting by Mrinalika Roy in Bengaluru; Modifying by Devika Syamnath)
